Background:
New treatment options are needed for patients (pts) with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), especially those with aggressive B-NHL. MBS303 is a CD20×CD3 T-cell-engaging bispecific antibody that has a novel 2:1 (CD20:CD3) configuration to kill malignant B cells. This dose-escalation phase Ⅰ trial evaluated the safety and efficacy of single-agent MBS303 in pts with R/R NHL (NCT05806099).
Methods:
Pts with refractory or relapse (R/R) NHL with ≥1 prior line of therapy that must including anti-CD20 antibody (diffuse large B-cell lymphoma not otherwise specified [DLBCL NOS], high-grade B-cell lymphoma [HGBCL], primary mediastinal large B-cell lymphoma [PMBCL], transformed follicular lymphoma [trFL] or follicular lymphoma [FL]) were enrolled. The dose-escalation part (7 cohorts ranging from 0.45 to 30 mg) of this phase I, multicenter, single-arm, open-label clinical trial has enrolled at 4 study sites in China. The study objectives include safety, dose finding (Recommended Phase II Dose), and antitumor activity. Eligible pts received intravenous (IV) step-up dosing (SUD) of MBS303 in a 28-day dose limiting toxicity (DLT) period, and then a target dose from C2D1 every 3 weeks for up to 17 cycles or until disease progression or unacceptable toxicity. Response was investigator-assessed using Lugano criteria (Cheson et al. JCO 2014).
Results:
As of Jul 20th, 2024, 4 cohorts were enrolled. Ten pts who received ≥1 dose of study treatment were evaluable. Median age was 56 years (range: 51-70), 70% were female and 80% of pts had Ann Arbor stage III/IV. The median number of prior therapies received was 2.5 (range: 1-4; ≥3 prior therapies: 50%). Most pts (80%) were refractory to prior therapy and 7 pts (70%) were refractory to any line of prior CD20 therapy. The median number of MBS303 cycles administered was 3.5 (range: 1-16).
Maximum tolerated dose was not reached. Three pts (30%) experienced cytokine release syndrome (CRS), and all were grade [G]1-2, no G 3 or higher. Most CRS occurred in 1st cycle, and resolved within 48 hours. No pts experienced neurologic events. Three pts (30%) experienced serious adverse events (SAE) related to MBS303, 2 pts with infection and 1 pt with aminotransferase increased.
In R/R B-NHL pts received MBS303 ≥9 mg (n=7), the objective response rate (ORR) was 71%, and complete metabolic response (CMR) was 43% (all in 9 mg). In FL pts of 9 mg (n=2), ORR and CMR were both 100%. Even at first cohort with target dose of 0.45 mg, response was also observed and this pt with r/r DLBCL achieved partial response.
Conclusion:
This study demonstrated that in pts with refractory, aggressive B-NHL, MBS303 showed favorable safety and remarkable antitumor activity in the preliminary data, even at low doses.
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal